Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | White Papers
Search Refinements

Drug Discovery & Development White Papers

View white papers from other Pharmaceutical sectors:
106-120 of 138 results
Target Immobilization and NMR Screening of Fragments in Early Drug Discovery
| By ZoBio
Using localized NMR spectroscopy on immobilized targets provides us with a method to simultaneously assess binding of small molecules to two different samples. This Target Immobilized NMR Screening (TINS) has a number of advantages, not least is the requirement for minimal quantities of non-isotopically labeled protein and the applicability to insoluble or unstable targets. The technique is sensitive to binding with KD values in the range of 100 nM to 20 mM, while careful selection of the reference protein reduces the number of false positive hits. This combination ensures a maximal number of valid hits from which to select starting points for hit elaboration projects. Hits can be prioritized using biological assays when appropriate, as well as an array of biophysical techniques. So far a variety of soluble proteins, including kinases, GTPases, viral targets and proteases, as well as a membrane protein, have been successfully screened against our fragment library. Here we illustrate our experiences with a number of examples which emphasize the usefulness of the method in selecting and prioritizing fragment hits for elaboration towards leads.
Drug Research > Drug Discovery & Development > White Papers
HPLC Analysis of Fluorescently labelled N-Glycans
| By Ludger
To enable the detection following separation of N-glycans by HPLC, the glycans are flourescently labelled with aryl amine compounds by reductive amination. The most commonly used flourescent label is 2-aminobenzamide (2AB), although 2-aminobenzoic acid (2-AA) and 2-aminopyride (2AP) are also used. The labelled glycans can then be analysed by a range of HPLC methods.
Drug Research > Drug Discovery & Development > White Papers
Win with Networked Drug Development Alliances
| By INC Research
Large biopharms are caught between two powerful market forces: the pressure to maximize profits and the need for continual investment in their drug pipelines. For drug development executives, choosing which drugs to commercialize is all about trade-offs -- for example, passing over many pre-clinical compounds to aggressively pursue the highest probability clinical trials that maximize the likelihood of near-term revenue and earnings. Executives know that passing over promising compounds could mean missing their next big hit.
Drug Research > Drug Discovery & Development > White Papers
A New Approach to Outsourced Drug Development
| By INC Research
A perfect storm is forming within the biopharmaceutical industry. With a growing number of blockbuster drugs losing patent protection, clinical research executives are under immense pressure to bring new drugs to market. As sponsor companies struggle to replace the revenue loss threatened by generics, drug development is becoming more complex and expensive.
Drug Research > Drug Discovery & Development > White Papers
Reducing Risk with the Right CRO Partner
| By INC Research
For drug developers, finding the right patients, investigators and outsourcing partners is essential. With shareholders demanding improved efficiencies, the resources, reach and expertise of a contract research organization (CRO) can expedite the research and development process.
Drug Research > Drug Discovery & Development > White Papers
CYNCRON - an Overview
| By CYNCRON
CYNCRON is a Nordic full-service clinical contract research organisation (CRO) with more than 25 years of experience, operating throughout Denmark, Sweden, Finland and Norway. We offer solid know-how and experience of clinical research, data management, biostatistics, pharmacovigilance and DMC/DSMB services for global and small pharma, biotech and medical device companies.
Drug Research > Drug Discovery & Development > White Papers
CYNCRON - a Full-Service Nordic Clinical Research Organisation (CRO)
| By CYNCRON
A data monitoring committee (DMC) / data safety monitoring board (DSMB) is an independent group of experts that monitors data from an ongoing clinical trial and gives recommendation to the sponsor regarding the best action to take. Cyncron can offer a range of DMC solutions ranging from assisting you in setting up the DMC with a charter, arranging meeting, delivery of packages to agreed timelines, and contact between the sponsor and the DMC.
Drug Research > Drug Discovery & Development > White Papers
Certainty Within Clinical Development
| By CYNCRON
There’s nothing like being sure. Especially in complicated projects where everything depends on the quality of the research. At Cyncron, our focus is to ensure that you have the conclusive information you need to make the right decisions. We are happy to provide credentials from other customers.
Drug Research > Drug Discovery & Development > White Papers
Vade Mecum for Thermal Analysis
| By SYSTAG
In the first part we would like to give a specific overview of methods and equipment principles which are currently on the market. Subsequently we must address the needs, which are then further examined, mainly for thermal safety techniques, because this is SYSTAG’s main area of activity.
Drug Research > Drug Discovery & Development > White Papers
A New 384 Well Storage Plate Reducing Compound Consumption and Supporting Assay Miniaturisation
| By Greiner Bio-One
Technical notes and applications for laboratory work. Please download this free white paper for more information.
Drug Research > Drug Discovery & Development > White Papers
Biotechnology Solution Brief
| By Brainloop
Biotech companies need to share highly confidential documents in parallel with multiple prospective licensing partners — some who may be competitors — while ensuring that none of these proprietary documents are compromised during the process.
Drug Research > Drug Discovery & Development > White Papers
Biovian - From Gene to Finished Vial
| By Biovian
Comprehensive information about Biovian, including detailed information on all services as well as examples.
Drug Research > Drug Discovery & Development > White Papers
Biovian Company Brochure
| By Biovian
From gene to finished vial — Biovian is your one-stop-shop providing full range services in cGMP contract manufacturing of biologicals.
Drug Research > Drug Discovery & Development > White Papers
Bridging the gap?
| By Genetic Analysis
GA-map™ technology platform - A rapid comprehensive high-throughput gut microbiota analysis. To find out more please download this free white paper.
Drug Research > Drug Discovery & Development > White Papers
106-120 of 138 results